Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04647487 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT04647487 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 87 participants.
The verdict
NCT04647487, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
Interventions
- DRUG LY3484356
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2022-11-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04647487
The ClinicalTrials.gov registry entry for NCT04647487 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3484356 is the first listed.
NCT04647487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04647487 about?
NCT04647487 is a clinical study titled "A Study of LY3484356 in Women With Breast Cancer Before Having Surgery". The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this st...
What is the current status of trial NCT04647487?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2021-04-21. Estimated completion is 2022-11-11.
What interventions are being tested in trial NCT04647487?
The interventions under investigation include: LY3484356 (DRUG).
Who is sponsoring clinical trial NCT04647487?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.